Global News

Medtronic to acquire Covidien for $42.9 billion

Monday, June 16, 2014 09:43 AM

Medtronic, a global medical technology, services and solutions company, has agreed to acquire Covidien, a global healthcare technology and medical supplies provider, in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic’s closing stock price of $60.70 per share on June 13. 

More... »

WIRB Copernicus Group

BioClinica acquires Blueprint Clinical to boost presence in risk-based monitoring

Monday, June 16, 2014 09:21 AM

In the scramble to harness technology to implement risk-based monitoring (RBM) strategies, BioClinica, a provider of technology-enhanced clinical trial management solutions, is acquiring Blueprint Clinical, a small Washington-based developer of Compass, a specialized software program that evaluates potential risks to patient safety and clinical trial operational performance.

More... »

CRF Health eCOA webinar series

The Pulse on Study Conduct

Monday, June 16, 2014 07:34 AM

Fourteen years ago as a new study coordinator, I was struggling to understand the responsibilities of managing several clinical trials.

More... »

KalGene Pharmaceuticals forms multi-year collaboration for aggressive cancers

Friday, June 13, 2014 01:14 PM

KalGene Pharmaceuticals, a developer of a prognostic marker and companion therapeutic that specifically targets aggressive cancers, has formed a multi-stage and multi-year collaboration with the Center for Imaging Technology Commercialization (CIMTEC), Sunnybrook Research Institute (SRI) and the Ontario Cancer Biomarker Network (OCBN) at Queen's University.

More... »

EntreMed stockholders approve name change to CASI Pharmaceuticals

Friday, June 13, 2014 01:13 PM

EntreMed, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, said its annual meeting of stockholders voted in favor of changing the company's corporate name to CASI Pharmaceuticals. The name change will occur June 16, with the rollout of a new web site, www.casipharmaceuticals.com.

More... »

Janssen R&D, Viiv Healthcare collaborate on maintenance treatment for HIV

Friday, June 13, 2014 01:08 PM

Janssen R&D Ireland has entered into a collaboration with ViiV Healthcare to develop and commercialize a new, single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT) and ViiV's Integrase Inhibitor dolutegravir (marketed as TIVICAY) as the sole active ingredients for the maintenance treatment of people living with human immunodeficiency virus (HIV). The companies will further investigate development of this drug combination for pediatric use.

More... »

DrugDev establishes DrugDev Innovation Lab, partners with two technology firms

Thursday, June 12, 2014 01:43 PM

DrugDev, a provider of technology-driven solutions that help investigators, sponsors and CROs conduct more trials together, has established the DrugDev Innovation Lab, a technology incubator designed to accelerate emerging solutions in clinical trial automation.

More... »

Latest AAHRPP accreditations include N.Y. State Department of Health

Thursday, June 12, 2014 01:40 PM

The Association for the Accreditation of Human Research Protection Programs has accredited three more organizations, including one of the nation's largest state health departments and India's national comprehensive cancer center. A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government.

More... »

TeraDiscoveries changes name to Cloud Pharmaceuticals

Thursday, June 12, 2014 01:38 PM

TeraDiscoveries, a bio-therapeutics company focused on cloud-based drug design and development, has changed its corporate name to Cloud Pharmaceuticals.

More... »

AstraZeneca in-licenses Synairgen's SNG001 for asthma in $232M deal

Thursday, June 12, 2014 01:38 PM

AstraZeneca has inked a global license agreement with Synairgen, a U.K. company specializing in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. SNG001 supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs